Flatiron Health’s Post

Appendix cancer specialists and their medical teams use various tools to diagnose this rare disease. We will use these throughout our journey to monitor our status, either living with No Evidence of Disease or Thriving with Disease. Be your best patient advocate by understanding what these tools are used for and what the results mean. You are entitled to ask questions; your physician or medical team member should help you be clear on your disease status, ongoing treatment plan, and short/long-term expectations. Tools include: 🧡Ultrasound 🧡CT scan 🧡MRI 🧡 Bloodwork (CBC, CMP with Differential) 🧡Tumor markers (usually CEA, CA19.9, and maybe CA125 or CA 120) 🧡Colonoscopy 🧡Biopsy Ultimately your best tool is how you feel. You know your bathroom patterns, your internal quirks, and feelings of general wellness. Start both an appendix cancer specialist you trust and move forward. We're in it for the long haul and we have hope for you! FInd a specialist (2nd and 3rd opinions are common place!): https://lnkd.in/esHc77xy #appendixcancerspecialist #findasurgeon #appendixcancerawarenessmonth #oneinamillion #beyourbestadvocate #diagnosis #treatment #wehavehopeforyou

40% of all dual expressor #NSCLC patients don't receive guideline-concordant care. Read that again. That is a shocking statistic. Our new analysis, led by Scott Phillips and co-authored with NeoGenomics Laboratories, investigated patient treatment pathways and the potentially deadly aftereffects. This is simply the tip of the iceberg. More in-depth research must be conducted to better understand the potential reasons for this deviation in standards of care, and what we can do to address them. It's stories like these that remind me why I do what I do. Komodo Health's mission is to reduce the burden of disease. Publishing analyses like these, using #RWE and our suite of analytics, goes one step further to both identify and help close gaps in care. https://lnkd.in/gq6t4PEe

This article discusses the unique methodological challenges faced by researchers and highlights innovative solutions that are paving the way for better diagnosis and treatment of rare disease research. Read the full article 👇🏻 #RareDisease #GeneticTesting #rarediseasediagnosis #ResearchAdvancements #ngs #genetictesting #3billion

Seth J. Baum, MD, Chief Medical Officer of Flourish Research and the Vice-Chair of the Board of the Family Heart Foundation, talks about the prevalence of homozygous familial hypercholesterolemia (HoFH) and when screening for the disease should occur. Watch this video below ⤵️ #HoFH #HomozygousFamilialHypercholesterolemia #AmericanHeartAssociation

🚨 Thrilled to share! The latest IRDiRC publication, "Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases", is now live on Orphanet Journal of Rare Diseases with open access!  This paper offers key insights and expert guidance on how cutting-edge technologies can revolutionize rare disease diagnostics. A valuable resource for anyone invested in advancing rare disease diagnosis and care.   #RareDiseases #InnovativeDiagnosis #TechForGood #OpenAccess #IRDiRC 🔗 https://lnkd.in/eJuZfz25

📣 Read all about it! An international group of over 550 people, including PPMI researchers, are calling for a standardized framework that would utilize objective measures to define #Parkinson's stages through biological markers, instead of disease symptoms. Read more here: https://lnkd.in/eePJYe3y

The biggest disease risk factor is one none of us can avoid: aging. That’s why my colleagues at AbbVie are researching age-related diseases – making big bets to invent treatment patients need. I am proud to be part of this innovative and inspiring Discovery Research organization. Great article on how our AbbVie-Calico teams are researching and discovering critical information about maintaining health as we age. See how: https://lnkd.in/ge9gCvuu . #WeAreAbbVie

Seth J. Baum, MD, Chief Medical Officer of Flourish Research and the Vice-Chair of the Board of the Family Heart Foundation, talks about the prevalence of homozygous familial hypercholesterolemia (HoFH) and when screening for the disease should occur. View this video below ⤵️ #HoFH #HomozygousFamilialHypercholesterolemia #FamilyHeartFoundation

🚨 Thrilled to share! The latest IRDiRC publication, "Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases", is now live on Orphanet Journal of Rare Diseases with open access! This paper offers key insights and expert guidance on how cutting-edge technologies can revolutionize rare disease diagnostics. A valuable resource for anyone invested in advancing rare disease diagnosis and care. #RareDiseases #InnovativeDiagnosis #TechForGood #OpenAccess #IRDiRC 🔗 https://lnkd.in/dJagJE83

Happy to share our new commentary on sex differences in atherosclerotic plaque vulnerability #atvbnet, Melody Chemaly, Sofija Vuckovic!